SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001144204-19-031037
Filing Date
2019-06-14
Accepted
2019-06-14 17:12:23
Documents
2
Group Members
DAN ORENDEXCEL PHARMA TECHNOLOGIES LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D tv523464_sc13d.htm SC 13D 87006
2 EXHIBIT 1 tv523464_ex1.htm EX-99.1 5218
  Complete submission text file 0001144204-19-031037.txt   93784
Mailing Address 1 DEXCEL STREET OR AKIVA L3 30600000
Business Address 1 DEXCEL STREET OR AKIVA L3 30600000 972-4-636404
Dexxon Holdings Ltd. (Filed by) CIK: 0001636684 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB (441) 295-5950
Myovant Sciences Ltd. (Subject) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: SC 13D | Act: 34 | File No.: 005-89732 | Film No.: 19899672
SIC: 2834 Pharmaceutical Preparations